발생일자 2015.07.10 

사건번호 1:15-cv-00589 

법원국가 UNITED STATES OF AMERICA 

관할법원명 D.C.Delaware(지방법원) 

침해권리 특허 

원고명 Celgene Corporation/ Astellas Pharma, Inc. ( 미국 / 외국기업 )  

피고명 Teva Pharmaceuticals USA, Inc. ( 미국 / 외국기업 )  

소송유형 침해금지 

[Celgene Corporation et al v. Teva Pharmaceuticals USA, Inc.] 사건번호 1:15-cv-00589에 따르면 원고 Celgene Corporation/ Astellas Pharma, Inc.는 피고 Teva Pharmaceuticals USA, Inc.을(를) 상대로 특허 US7608280|US7611724을(를) 침해하였다는 이유로 미국 델라웨어 지방법원에 소를 제기하였다. 

분쟁결과 분쟁중 

산업분류 화학∙바이오 > 의약품 

계쟁제품 Romidepsin for injection - Generic version of Celgene's ISTODAX� 

지재권번호/명칭

US7608280   Method of producing FR901228 

US7611724   Method of producing FR901228 

Depsipeptides and congeners thereof are disclosed having structure (I), wherein m, n, p, q, X, R1, R2 and R3 are as defined herein. These compounds, including FR901228, have activity as, for example, immunosuppressants, as well as for the prevention or treatment of patients suffering or at risk of suffering from inflammatory, autoimmune or immune system-related diseases including graft-versus-host disease and enhancement of graft/tissue survival following transplant. Also provided are methods for inhibiting lymphocyte activation, proliferation, and/or suppression of IL-2 secretion. Also provided are crystalline forms of FR901228, e.g., type A and type B crystalline forms of FR901228. 

 1. A type B crystalline form of compound FR901228: ##STR00002## 

 2. The type B crystalline form of claim 1 obtained from hexanes. 

 3. A type B crystalline form of compound FR901228: ##STR00003## which crystalline form is characterized by a powder X-ray diffraction pattern substantially similar to FIG. 5. 

 4. A composition comprising a type B crystalline form of compound FR901228: ##STR00004## wherein the composition is characterized by having one or more peaks in its X-ray diffraction pattern selected from those at about 7.1, about 11.7, about 11.9, and about 15.1 degrees 2-theta. 

 5. The composition of claim 4, wherein the composition is characterized by having two or more peaks in its powder X-ray diffraction pattern selected from those at about 7.1, about 11.7, about 11.9, and about 15.1 degrees 2-theta. 

 6. The composition of claim 4, wherein the composition is characterized by having three or more peaks in its powder X-ray diffraction pattern selected from those at about 7.1, about 11.7, about 11.9, and about 15.1 degrees 2-theta. 

 7. The composition of claim 4, wherein the composition is characterized by having four peaks in its powder X-ray diffraction pattern at about 7.1, about 11.7, about 11.9, and about 15.1 degrees 2-theta.